Low-Dose Aspirin’s Impact on PI3K-Altered Localized Colorectal Cancer: New Evidence from a Randomized Controlled Trial
Highlight
– Daily low-dose aspirin (160 mg) significantly reduces the 3-year colorectal cancer recurrence rate in patients harboring somatic PIK3CA hotspot mutations (exon 9 or 20).
– Aspirin shows a similar beneficial effect on disease recurrence in patients with additional moderate- to high-impact somatic variants in the PI3K pathway genes PIK3CA, PIK3R1, or PTEN.
– Disease-free survival was numerically improved with aspirin, though not always statistically significant depending on subgroup.
– Safety profile shows a modest increase in severe adverse events with aspirin use relative to placebo.
Study Background and Disease Burden
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.